A multi-component injection

Pending Publication Date: 2019-09-05
TIANJIN CHASE SUN PHARM CO LTD
View PDF0 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent describes a method of reducing the expression of a protein called TF in sepsis rats using a multi-component injection. The invention has been tested and found to be stable, safe, and effective in reducing the inflammation and coagulation dysfunction associated with sepsis. The method involves injecting a combination of different components into the rats at specific times, resulting in a reduction of TF expression in the liver and lungs at 24 hours after the operation. The invention has been shown to improve the function of monocytes and reduce the risk of TF expression in sepsis rats.

Problems solved by technology

However, there are not enough specific medicines put into clinical practice aiming at the pathogenesis of Sepsis.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A multi-component injection
  • A multi-component injection
  • A multi-component injection

Examples

Experimental program
Comparison scheme
Effect test

embodiment 2 preparation

of Multi-Component Injection

[0117]providing 100 g of Red Paeony Root decoction pieces; heating and boiling the Red Paeony Root decoction pieces with process water of 10 times the weight of the Red Paeony Root decoction pieces to obtain a first decoction after 2 hours slight boiling; filtering the first decoction to obtain filtrate I and a first dreg; boiling the first dreg with process water of 8 times the weight of the first dreg to obtain a second decoction after 1 hour slight boiling; filtering the second decoction to obtain filtrate II and a second dreg; mixing filtrate I and filtrate II to obtain a mixture; concentrating the mixture to obtain a first concentrate of 100 ml; adding a proper amount of gelatin solution to the first concentrate under stirring to obtain a gelatin-containing first concentrate; adding 95% ethanol to the gelatin-containing first concentrate to obtain an ethanol-containing first concentrate having an ethanol volume content of 70%; storing the ethanol-con...

embodiment 3 preparation

Process of Multi-Component Injection

[0120]providing 100 g of safflower carthamus decoction pieces; leaching the safflower carthamus decoction pieces with 30% ethanol of 8 times the weight of the safflower carthamus decoction pieces for 8 hours to obtain a leach liquor; filtering the leach liquor to obtain a liquid medicine of 4-6 times the weight of the safflower carthamus decoction pieces; adding 95% ethanol to the liquid medicine to obtain an ethanol-containing liquid medicine having an ethanol volume content of 70%; storing the ethanol-containing liquid medicine under cooling condition for 48 hours to obtain a cool ethanol-containing liquid medicine; filtering the cool ethanol-containing liquid medicine to obtain a first filtrate; concentrating the first filtrate under reduced pressure to obtain a concentrate of 100 ml; adding 95% ethanol to the concentrate to obtain an ethanol-containing concentrate having an ethanol volume content of 80%; storing the ethanol-containing concentr...

embodiment 4 preparation

Process of Multi-Component Injection

[0124]providing 100 g of safflower carthamus decoction pieces; leaching the safflower carthamus decoction pieces with 30% ethanol of 8 times the weight of the safflower carthamus decoction pieces for 8 hours to obtain a leach liquor; filtering the leach liquor to obtain a liquid medicine of 4-6 times the weight of the safflower carthamus decoction pieces; adding 95% ethanol to the liquid medicine to obtain an ethanol-containing liquid medicine having an ethanol volume content of 70%; storing the ethanol-containing liquid medicine under cooling condition for 48 hours to obtain a cool ethanol-containing liquid medicine; filtering the cool ethanol-containing liquid medicine to obtain a first filtrate; concentrating the first filtrate under reduced pressure to obtain a concentrate of 100 ml; adding 95% ethanol to the concentrate to obtain an ethanol-containing concentrate having an ethanol volume content of 80%; storing the ethanol-containing concentr...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Fractionaaaaaaaaaa
Fractionaaaaaaaaaa
Fractionaaaaaaaaaa
Login to View More

Abstract

The invention relates to the technical field of medicines, and particularly relates to a multi-component injection and preparation processes and applications thereof. In the present invention, the effective ingredients of safflower carthamus. Red Paeony Root, Ligusticum wallichii, radix salviae miltiorrhizae and Angelica sinensis are analyzed and a multi-component injection is prepared via the modern pharmaceutical preparation technology. The study proves that the multi-component injection of the invention has therapeutic effects on Sepsis.

Description

I. TECHNICAL FIELD[0001]The present invention relates to the technical field of medical technology, and particularly relates to a multi-component injection and preparation processes and applications thereof.II. BACKGROUND OF THE INVENTION[0002]Sepsis is a fatal organ dysfunction caused by the reaction disorder of the infected hosts, with a hospital mortality of more than 10%, which has posed a huge threat to human health, becoming a focus to which the medical field pays close attention [see JAMA. 2016 Feb. 23; 315(8):801-10]. Under the big data retrospective analysis in combination with the microarray technology and analysis of leukocyte gene expression, people gradually realize that Sepsis is not only a process of systemic inflammatory reaction or immune disorder, but also a complex chronic critical disease combining sustained inflammation, immunosuppression and catabolism. [See J Trauma Acute Care Surg. 2012 June; 72(6): 1491-501, BMJ. 2016 May 23; 353: i1585 and Medicine (Baltimo...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K9/00A61K31/7048A61K31/192A61K31/235A61K31/353A61K36/65A61K31/513A61K31/52A61K31/198A61K31/7064A61K31/7076A61K31/194A61K36/28A61K31/708A61K31/343A61K36/236A61K36/232A61K36/537A61P31/04
CPCA61K9/0019A61K2236/53A61K31/192A61K31/235A61K31/353A61K36/65A61K31/513A61K31/52A61K31/198A61K31/7064A61K31/7076A61K31/194A61K36/28A61K31/708A61K31/343A61K36/236A61K36/232A61K36/537A61P31/04A61K2236/39A61K2236/333A61K2236/331A61K2236/37A61K31/7048A61K47/26A61K9/08A61K2300/00A61K36/286
InventorYAO, XIAOQINGSUN, CHANGHAIDONG, KAILI, CHUANZHANG, GUIPINGDONG, TIANHAOCAO, JINGWANG, QIYUNLI, XIANJUNGAO, JUNMINSUN, MINGZHEN
OwnerTIANJIN CHASE SUN PHARM CO LTD